Business context and reporting period
Filing identity: The supplied filing is Nemus Bioscience, Inc.’s Form 10-K for the fiscal year ended December 31, 2017, filed March 19, 2018. It does not identify Skye Bioscience, Inc.; verify that this is the intended filing.
Nemus is an early-stage biopharmaceutical company developing cannabinoid-based therapeutics under University of Mississippi (UM) licenses. Its candidates address glaucoma and other eye disorders, chemotherapy-related symptoms, and MRSA. Candidates remained in research or preclinical development; the company had no approved products or product revenue.
Financial results and liquidity
| Metric | 2017 | 2016 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $3.859 million | $4.471 million |
| Research and development | $311,302 | $939,040 |
| General and administrative | $3.548 million | $3.532 million |
| Operating loss | $3.859 million | $4.471 million |
| Net loss | $3.094 million | $3.178 million |
| Net loss per common share | $0.11 | $0.17 |
| Cash used in operations | $3.298 million | $3.553 million |
| Cash and cash equivalents at year-end | $259,955 | $64,820 |
Margins are not meaningful because there was no revenue. The 2017 net loss benefited from approximately $767,000 of non-cash fair-value income on warrants and preferred-stock-related features; operating expenses therefore better reflect ongoing operating losses. Net loss attributable to common shareholders was $4.138 million in 2017 versus $3.503 million in 2016, including preferred deemed dividends of $1.044 million and $325,000, respectively.
At December 31, 2017, total assets were $557,218, total liabilities $1.357 million, and stockholders’ deficit $3.570 million. Current assets of $556,000 were below current liabilities of $806,000. The company had $500,000 outstanding under a secured convertible bridge loan, bearing 12% interest and due June 30, 2018 unless converted; the loan was secured by company assets. No operating margin or cash runway beyond management’s stated estimates is presented here.
Material changes versus the prior period
- Operating expenses fell 14%, largely because R&D spending declined about 67% amid limited cash; management reported minimal formulation work in 2017. G&A was nearly flat.
- Operating cash use improved by about $255,000, but remained substantial relative to year-end cash.
- Financing activities provided $3.513 million in 2017, compared with $408,000 in 2016, including Series D and F preferred-stock proceeds and the convertible loan.
- The company added an exclusive UM license for UM 5070, a cannabinoid-based infectious-disease platform. Several preferred-stock conversions and lower-price financings reset conversion and warrant exercise prices, increasing potential dilution.
Outlook, risks, contingencies, and unusual items
- Funding and going concern: The auditor cited recurring losses and substantial doubt about the company’s ability to continue as a going concern. Management said available cash was expected to fund at least four months, and that without additional funding it could not meet obligations beyond one year after the financial statements were issued. Continued operations depend on further financing.
- Subsequent financing and control: In January and February 2018, Emerald Health Sciences funded the remaining $400,000 bridge-loan amount, the $900,000 loan converted into common shares, and financings generated $3.25 million in aggregate gross equity proceeds. The first closing gave Emerald a majority ownership interest and led to board changes. These transactions materially changed ownership and capitalization after year-end.
- Pipeline outlook: Management described further preclinical work, including possible human testing of NB1111 only after an effective IND and regulatory clearance. It said it would reassess NB1222’s commercial priority. These are plans, not assured milestones; the filing provides no revenue guidance.
- Key risks: All programs are early-stage; the company depends heavily on UM and third-party research and manufacturing. Cannabis-derived products face stringent federal controlled-substance and DEA requirements, and FDA approval, clinical success, manufacturing access, and commercialization are uncertain.
- Contingency: A proposed $20 million Series E financing did not close, and the guarantor did not pay under its guarantee. Nemus commenced arbitration in November 2017; recovery is uncertain.
- Other investor risks: Common shares traded thinly on the OTCQB. As of March 15, 2018, the filing reported 100.1 million common shares outstanding, alongside substantial warrants and preferred-stock conversion rights. Preferred-stock redemption provisions and additional share issuance could affect liquidity and ownership.
- Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2017; the auditor did not attest to internal-control effectiveness.
Most important facts to verify
- Confirm whether the intended issuer is Nemus Bioscience or Skye Bioscience; the filing names Nemus.
- Review the auditor’s going-concern paragraph, cash runway disclosures, and actual financing and spending after year-end.
- Verify the terms, completion, and dilution effects of Emerald’s financings, the loan conversion, warrants, preferred stock, and resulting control change.
- Check the status and expected recovery of the $20 million Series E arbitration claim; do not treat the claimed amount as available cash.
- Confirm current pipeline status, regulatory and DEA permissions, and UM and contract-manufacturer arrangements before relying on development timelines.
- Reconcile year-end debt and conversion-related liabilities with the 2018 conversions and assess any preferred-stock redemption triggers.